Linda L. Lloyd

When selecting the optimum phase for SEC separations, several key column parameters must be considered carefully.

With many new biopharmaceuticals now being developed, robust analytical methods are needed to ensure that these protein-based drugs are of high purity and safe with a minimum amount of side effects. Size-exclusion chromatography is an important technique in investigating purity and is useful to identify and monitor protein aggregation, which can have economic and immunogenicity effects. This article discusses those column parameters that are most important in the selection of the optimum phase for SEC separations.

Size-exclusion chromatography is an important technique in biopharmaceutical characterization. This article discusses its use for soluble aggregation analysis and quantitation.

Size-exclusion chromatography is an important technique in biopharmaceutical characterization. This article discusses its use for soluble aggregation analysis and quantitation.

Introduction

Out of the several options available for retaining polar compounds like nucleotides, this application note focuses on the use of polar-modified C18 bonded phases for their analysis.

Bradykinin, a 9 amino acid peptide, is a physiologically and pharmacologically active peptide of the kinin group of proteins, which is used in the development of antagonists and therapies for hereditary angioedema. In this application, 50 mg of crude bradykinin, synthesised on a StratoSpheresâ„¢ PL-Rink resin, is purified using an HPLC method that can be scaled from the laboratory through to full production.